Psychedelic Therapy Research: The State of the Art
Neal M. Goldsmith, Ph.D., Rick Doblin, Ph.D., Michael Mithoefer, M.D., and Bill A. Richards, Ph.D.
20% off online discount: use code ONLINE20
We are in the midst of a “psychedelic renaissance” of extraordinary research at Johns Hopkins, Harvard, and other top medical schools. This webinar series will share the powerful findings of this leading-edge research with four leaders in this exciting new work. We will use interactive discussions and audience participation.
This Webinar:
Psychedelics by Prescription: A Strategy
Rick Doblin, Ph.D., Executive Director, Multidisciplinary Association for Psychedelic Studies
Neal M. Goldsmith, Ph.D., Moderator
The Multidisciplinary Association for Psychedelic Studies (MAPS, www.maps.org) is a non-profit pharmaceutical company focusing on developing the therapeutic uses of psychedelics and marijuana into FDA-approved prescription medicines. Rick will discuss MAPS’ overall strategy and report on studies of MDMA, LSD, ibogaine, ayahuasca and marijuana.
